Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (419) 419
female (337) 337
index medicus (232) 232
hot flashes - chemically induced (227) 227
middle aged (222) 222
hot flashes - drug therapy (149) 149
aged (136) 136
hot flashes (129) 129
menopause (129) 129
postmenopausal women (129) 129
adult (112) 112
oncology (110) 110
breast neoplasms - drug therapy (109) 109
male (103) 103
antineoplastic agents, hormonal - adverse effects (87) 87
obstetrics & gynecology (84) 84
breast cancer (77) 77
treatment outcome (73) 73
quality of life (70) 70
hot temperature (69) 69
quality-of-life (65) 65
hormone replacement therapy (64) 64
breast-cancer (63) 63
prostatic neoplasms - drug therapy (63) 63
postmenopause (61) 61
cancer (60) 60
tamoxifen (60) 60
estrogen replacement therapy - adverse effects (59) 59
tamoxifen - adverse effects (59) 59
women (59) 59
risk factors (58) 58
breast neoplasms - chemically induced (55) 55
care and treatment (55) 55
aged, 80 and over (53) 53
animals (51) 51
therapy (50) 50
androgen antagonists - adverse effects (47) 47
analysis (46) 46
antineoplastic agents, hormonal - therapeutic use (46) 46
vasomotor symptoms (46) 46
hot flashes - therapy (44) 44
randomized controlled trials as topic (44) 44
prostate cancer (42) 42
double-blind method (41) 41
health aspects (41) 41
randomized controlled-trial (41) 41
estrogen (38) 38
medicine, general & internal (38) 38
pharmacology & pharmacy (37) 37
prospective studies (36) 36
risk (36) 36
hot flashes - prevention & control (34) 34
menopausal symptoms (34) 34
double-blind (33) 33
research (33) 33
surveys and questionnaires (33) 33
aromatase inhibitors - adverse effects (32) 32
menopause - drug effects (32) 32
osteoporosis (31) 31
osteoporosis, postmenopausal - prevention & control (31) 31
survivors (31) 31
hot flushes (30) 30
selective estrogen receptor modulators - adverse effects (30) 30
article (29) 29
cardiovascular diseases - chemically induced (29) 29
estrogen replacement therapy (29) 29
estrogen replacement therapy - methods (29) 29
management (29) 29
tamoxifen - therapeutic use (29) 29
time factors (29) 29
trial (29) 29
drug therapy (28) 28
selective estrogen receptor modulators - therapeutic use (28) 28
women's health (28) 28
medicine & public health (27) 27
antineoplastic agents - adverse effects (26) 26
bone-mineral density (26) 26
breast neoplasms - prevention & control (26) 26
clinical trials (26) 26
severity of illness index (26) 26
androgen antagonists - therapeutic use (25) 25
dose-response relationship, drug (25) 25
estrogen plus progestin (25) 25
flushes (25) 25
hot flashes - physiopathology (25) 25
estrogens - therapeutic use (24) 24
prevention (24) 24
side effects (24) 24
raloxifene (23) 23
urology & nephrology (23) 23
chemotherapy, adjuvant (22) 22
hormone therapy (22) 22
prevalence (22) 22
aromatase inhibitors (21) 21
arthralgia - chemically induced (21) 21
hormone replacement therapy - adverse effects (21) 21
replacement therapy (21) 21
carcinoma (20) 20
endocrinology & metabolism (20) 20
symptoms (20) 20
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (14) 14
Engineering & Comp. Sci. - Stacks (10) 10
UTL at Downsview - May be requested (7) 7
UofT at Mississauga - Stacks (4) 4
Physics - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Chemistry (A D Allen) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Long overdue (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (550) 550
Japanese (17) 17
French (6) 6
Spanish (6) 6
German (5) 5
Chinese (1) 1
Dutch (1) 1
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
by Shore, Neal D, Dr and Chowdhury, Simon, MD and Villers, Arnauld, Prof and Klotz, Laurence, MD and Siemens, D Robert, Prof and Phung, De, BSc and van Os, Steve, MD and Hasabou, Nahla, MD and Wang, Fong, MD and Bhattacharya, Suman, PhD and Heidenreich, Axel, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 153 - 163
Summary Background Enzalutamide is an oral androgen-receptor inhibitor that has been shown to improve survival in two placebo-controlled phase 3 trials, and is... 
Hematology, Oncology and Palliative Medicine | TRIAL | THERAPY | ONCOLOGY | GUIDELINES | MEN | ANTIANDROGEN WITHDRAWAL SYNDROME | CRPC | CHEMOTHERAPY | Back Pain - chemically induced | Phenylthiohydantoin - adverse effects | Dyspnea - chemically induced | Myocardial Infarction - chemically induced | Anilides - therapeutic use | Nausea - chemically induced | Phenylthiohydantoin - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Male | Fatigue - chemically induced | Patient Dropouts | Arthralgia - chemically induced | Fractures, Spontaneous - chemically induced | Hypertension - chemically induced | Aged, 80 and over | Hydronephrosis - chemically induced | Double-Blind Method | Anemia - chemically induced | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Constipation - chemically induced | Disease-Free Survival | Tosyl Compounds - adverse effects | Tosyl Compounds - therapeutic use | Aged | Nitriles - adverse effects | Heart Failure - chemically induced | Hot Flashes - chemically induced | Nitriles - therapeutic use | Care and treatment | Cancer patients | Oncology, Experimental | Clinical trials | Metastasis | Research | Prostate cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
by Nguyen, Paul L and Alibhai, Shabbir M.H and Basaria, Shehzad and D’Amico, Anthony V and Kantoff, Philip W and Keating, Nancy L and Penson, David F and Rosario, Derek J and Tombal, Bertrand and Smith, Matthew R
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 5, pp. 825 - 836
Abstract Context Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive and advanced prostate cancer, but it has also been... 
Urology | Prostate cancer | Androgen deprivation therapy | PROPHYLACTIC BREAST IRRADIATION | BONE-MINERAL DENSITY | RANDOMIZED CONTROLLED-TRIAL | ADVANCED PROSTATE-CANCER | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | PHYSICAL-ACTIVITY | BICALUTAMIDE MONOTHERAPY | QUALITY-OF-LIFE | HORMONE AGONIST | SUPPRESSION PLUS RADIATION | Gynecomastia - chemically induced | Humans | Male | Metabolic Diseases - chemically induced | Muscle Proteins - drug effects | Bone Diseases, Metabolic - chemically induced | Antineoplastic Agents, Hormonal - adverse effects | Body Composition - drug effects | Antineoplastic Agents, Hormonal - therapeutic use | Androgen Antagonists - therapeutic use | Cardiovascular Diseases - chemically induced | Quality of Life - psychology | Androgen Antagonists - adverse effects | Hot Flashes - chemically induced | Prostatic Neoplasms - drug therapy | Practice Guidelines as Topic | Medical policy | Physiological aspects | Medical colleges | Complications and side effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
by Paul E. Goss and James N. Ingle and Kathleen I. Pritchard and Matthew J. Ellis and George W. Sledge and G. Thomas Budd and Manuela Rabaglio and Rafat H. Ansari and David B. Johnson and Richard Tozer and David P. D'Souza and Haji Chalchal and Silvana Spadafora and Vered Stearns and Edith A. Perez and Pedro E.R. Liedke and Istvan Lang and Catherine Elliott and Karen A. Gelmon and Judy-Anne W. Chapman and Lois E. Shepherd
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 11, pp. 1398 - 1404
Purpose In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors... 
NONSTEROIDAL AROMATASE INHIBITORS | ONCOLOGY | ADJUVANT ENDOCRINE THERAPY | TAMOXIFEN | ADHERENCE | Triazoles - adverse effects | Osteoporosis - chemically induced | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Treatment Outcome | History, 18th Century | Breast Neoplasms - drug therapy | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Time Factors | Breast Neoplasms - pathology | Postmenopause | Female | Aged | Androstadienes - therapeutic use | Hypercholesterolemia - chemically induced | Nitriles - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Hot Flashes - chemically induced | Nitriles - therapeutic use | Triazoles - therapeutic use | Index Medicus | ORIGINAL REPORTS | Bc7
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
by Matthew P. Goetz and James M. Rae and Vera J. Suman and Stephanie L. Safgren and Matthew M. Ames and Daniel W. Visscher and Carol Reynolds and Fergus J. Couch and Wilma L. Lingle and David A. Flockhart and Zeruesenay Desta and Edith A. Perez and James N. Ingle
Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 36, pp. 9312 - 9318
Purpose Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamox; ifen metabolites, but their effect on clinical outcome is... 
BREAST-CANCER | CYP3A | PHARMACOKINETICS | ONCOLOGY | GENOTYPE | METABOLIZING-ENZYMES | Tamoxifen - metabolism | Cytochrome P-450 CYP2D6 - genetics | Pharmacogenetics | Cytochrome P-450 CYP3A | Humans | Middle Aged | Risk Factors | Neoplasm Recurrence, Local | Cytochrome P-450 Enzyme System - metabolism | Genotype | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - metabolism | Polymorphism, Genetic | Antineoplastic Agents, Hormonal - adverse effects | Breast Neoplasms - genetics | Aged, 80 and over | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 Enzyme System - genetics | Adult | Female | Aged | Tamoxifen - adverse effects | Hot Flashes - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women
by Joffe, Hadine and Crawford, Sybil L and Freeman, Marlene P and White, David P and Bianchi, Matt T and Kim, Semmie and Economou, Nicole and Camuso, Julie and Hall, Janet E and Cohen, Lee S
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 10/2016, Volume 101, Issue 10, pp. 3847 - 3855
Context: Women are at increased risk for mood disturbance during the menopause transition. Hot flashes (HFs), sleep disruption, and fluctuating estradiol... 
BREAST-CANCER | BAZEDOXIFENE/CONJUGATED ESTROGENS | MOOD | VASOMOTOR SYMPTOMS | ENDOCRINOLOGY & METABOLISM | RANDOMIZED-TRIAL | PERIMENOPAUSAL WOMEN | MIDDLE-AGED WOMEN | HORMONE AGONIST | MASS-SPECTROMETRY | MENOPAUSAL TRANSITION | Estradiol - blood | Estradiol - metabolism | Sleep Wake Disorders - chemically induced | Humans | Middle Aged | Gonadotropin-Releasing Hormone - pharmacology | Hot Flashes - metabolism | Healthy Volunteers | Fertility Agents, Female - pharmacology | Young Adult | Sleep Wake Disorders - metabolism | Depression - metabolism | Menopause - metabolism | Leuprolide - administration & dosage | Depression - chemically induced | Adolescent | Adult | Fertility Agents, Female - administration & dosage | Gonadotropin-Releasing Hormone - agonists | Hot Flashes - chemically induced | Leuprolide - pharmacology | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial
by Smith, Ian and Yardley, Denise and Burris, Howard and De Boer, Richard and Amadori, Dino and McIntyre, Kristi and Ejlertsen, Bent and Gnant, Michael and Jonat, Walter and Pritchard, Kathleen I and Dowsett, Mitch and Hart, Lowell and Poggio, Susan and Comarella, Lisa and Salomon, Herve and Wamil, Barbara and O'Shaughnessy, Joyce
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 10, pp. 1041 - 1048
Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in... 
WOMEN | PLASMA ESTROGEN-LEVELS | ATAC TRIAL | EXEMESTANE | ONCOLOGY | TAMOXIFEN | BODY-MASS INDEX | ENDOCRINE THERAPY | AROMATASE INHIBITORS | BIG 1-98 | AROMATIZATION | Dyspnea - chemically induced | Triazoles - adverse effects | Myalgia - chemically induced | Humans | Middle Aged | Receptors, Estrogen - analysis | Arthralgia - chemically induced | Breast Neoplasms - therapy | Antineoplastic Agents, Hormonal - adverse effects | Receptors, Progesterone - analysis | Antineoplastic Agents, Hormonal - therapeutic use | Depression - chemically induced | Hypertension - chemically induced | Mastectomy | Postmenopause | Female | Chemotherapy, Adjuvant | Triazoles - therapeutic use | Anastrozole | Survival Rate | Lymphatic Metastasis | Disease-Free Survival | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Nitriles - adverse effects | Hot Flashes - chemically induced | Letrozole | Nitriles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors
by Gary Elkins and Joel Marcus and Vered Stearns and Michelle Perfect and M. Hasan Rajab and Christopher Ruud and Lynne Palamara and Timothy Keith
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 31, pp. 5022 - 5026
Purpose Hot flashes are a significant problem for many breast cancer survivors. Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased... 
PILOT EVALUATION | PAIN | MANAGEMENT | DIARY | ONCOLOGY | SCALE | POSTMENOPAUSAL WOMEN | TRANSDERMAL CLONIDINE | SEVERITY | SOY PHYTOESTROGENS | HYDROCHLORIDE | Severity of Illness Index | Prospective Studies | Humans | Middle Aged | Treatment Outcome | Hot Flashes - prevention & control | Breast Neoplasms - drug therapy | Activities of Daily Living | Antineoplastic Agents, Hormonal - adverse effects | Hot Flashes - psychology | Hot Flashes - physiopathology | Sleep | Quality of Life | Female | Hypnosis | Survivors - psychology | Hot Flashes - chemically induced | Breast Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial
by Annelies H. Boekhout and Andrew D. Vincent and Otilia B. Dalesio and Joan van den Bosch and Joke H. Foekema-Töns and Sandra Adriaansz and Sylvia Sprangers and Bastiaan Nuijen and Jos H. Beijnen and Jan H.M. Schellens
Journal of Clinical Oncology, ISSN 0732-183X, 10/2011, Volume 29, Issue 29, pp. 3862 - 3868
Purpose Therapies for breast cancer may induce hot flashes that can affect quality of life. We undertook a double-blind, placebo-controlled trial with the... 
WOMEN | IMPACT | THERAPY | ONCOLOGY | TAMOXIFEN | PHASE-III | MENOPAUSAL SYMPTOMS | PREVALENCE | QUESTIONNAIRE | GABAPENTIN | ADHERENCE | Hot Flashes - drug therapy | Analgesics - therapeutic use | Double-Blind Method | Humans | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | Treatment Outcome | Clonidine - therapeutic use | Hot Flashes - etiology | Breast Neoplasms - drug therapy | Venlafaxine Hydrochloride | Breast Neoplasms - complications | Cyclohexanols - therapeutic use | Placebos | Adult | Female | Aged | Hot Flashes - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
by Taylor, Hugh S and Giudice, Linda C and Lessey, Bruce A and Abrao, Mauricio S and Kotarski, Jan and Archer, David F and Diamond, Michael P and Surrey, Eric and Johnson, Neil P and Watts, Nelson B and Gallagher, J. Chris and Simon, James A and Carr, Bruce and Dmowski, W. Paul and Leyland, Nicholas and Rowan, Jean P and Duan, W. Rachel and Ng, Juki and Schwefel, Brittany and Thomas, James W and Jain, Rita I and Chwalisz, Kristof
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 1, pp. 28 - 40
In two randomized trials, two different doses of the oral gonadotropin-releasing hormone antagonist elagolix significantly reduced endometriosis-related... 
WOMEN | MEDICINE, GENERAL & INTERNAL | DEPOT MEDROXYPROGESTERONE ACETATE | CHRONIC PELVIC PAIN | MANAGEMENT | COSTS | ADD-BACK | QUALITY-OF-LIFE | BURDEN | Dysmenorrhea - drug therapy | Humans | Middle Aged | Endometriosis - complications | Dose-Response Relationship, Drug | Young Adult | Hydrocarbons, Fluorinated - administration & dosage | Pelvic Pain - drug therapy | Lipids - blood | Adult | Female | Double-Blind Method | Premenopause | Pyrimidines - administration & dosage | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Endometriosis - drug therapy | Estrogen Antagonists - administration & dosage | Bone Density - drug effects | Pelvic Pain - etiology | Adolescent | Dysmenorrhea - etiology | Estrogen Antagonists - adverse effects | Pyrimidines - adverse effects | Hot Flashes - chemically induced | Hydrocarbons, Fluorinated - adverse effects | Antagonists (Biochemistry) | Gonadotropin releasing hormone | Endometriosis | Dosage and administration | Research | Drug therapy | Dysmenorrhea | Side effects | Pain | Analgesics | Womens health | Clinical trials | Gonadotropins | Bone mineral density | Gonadotropin-releasing hormone | Drug dosages | Endometrium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Yoga of Awareness program for menopausal symptoms in breast cancer survivors: Results from a randomized trial
by Carson, James W and Carson, Kimberly M and Porter, Laura S and Keefe, Francis J and Seewaldt, Victoria L
Supportive Care in Cancer, ISSN 0941-4355, 10/2009, Volume 17, Issue 10, pp. 1301 - 1309
Breast cancer survivors have limited options for the treatment of hot flashes and related symptoms. Further, therapies widely used to prevent recurrence in... 
Breast cancer | Yoga | Pain | Meditation | Hot flashes | QUALITY | TERM | EXERCISE | HOT FLUSHES | WOMEN | THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | OSTEOARTHRITIS | INTERVENTION | Severity of Illness Index | Humans | Menopause | Middle Aged | Treatment Outcome | Exercise Therapy | Breast Neoplasms - rehabilitation | Pilot Projects | Quality of Life | Adult | Female | Aged | Survivors - psychology | Hot Flashes - therapy | Hot Flashes - chemically induced | Women | Clinical trials
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide
by Krull, AA and Larsen, SA and Clifton, DK and Neal-Perry, G and Steiner, RA
ENDOCRINOLOGY, ISSN 0013-7227, 10/2017, Volume 158, Issue 10, pp. 3259 - 3268
Vasomotor symptoms (VMS; or hot flashes) plague millions of reproductive-aged men and women who have natural or iatrogenic loss of sex steroid production. Many... 
WOMEN | B/DYNORPHIN KNDY NEURONS | GONADOTROPIN-RELEASING-HORMONE | CORE BODY-TEMPERATURE | MOUSE | ENDOCRINOLOGY & METABOLISM | MENOPAUSAL FLUSHES | SECRETION | ARCUATE NUCLEUS | TAIL SKIN | KISSPEPTIN NEURONS | Capsaicin - pharmacology | Mice, Inbred C57BL | Proto-Oncogene Proteins c-fos - analysis | Receptors, Neurokinin-3 - agonists | Adaptation, Physiological - physiology | Behavior, Animal - physiology | Male | Peptide Fragments - pharmacology | Substance P - pharmacology | Hot Temperature | Preoptic Area - chemistry | Preoptic Area - physiopathology | Body Temperature | Receptors, Neurokinin-3 - physiology | Animals | Hot Flashes - physiopathology | Female | Mice | Substance P - analogs & derivatives | Hot Flashes - chemically induced | Skin Temperature | Disease Models, Animal | Adaptations | Temperature | Animal models | Senktide | Temperature preferences | Preoptic area | Capsaicin | Body temperature | Thermoregulation | Capsaicin receptors | Thermocline | Hypothalamus | Plague | Neurokinin B | Autonomic nervous system | Temperature effects | Neurokinin | Rodents | Skin temperature | Skin | Hormone replacement therapy | Behavior | Temperature control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol
by Joffe, Hadine and White, David P and Crawford, Sybil L and McCurnin, Kristin E and Economou, Nicole and Connors, Stephanie and Hall, Janet E
Menopause: The Journal of The North American Menopause Society, ISSN 1072-3714, 09/2013, Volume 20, Issue 9, pp. 905 - 914
OBJECTIVEThe impact of hot flashes on sleep is of great clinical interest, but results are inconsistent, especially when both hot flashes and sleep are... 
Vasomotor symptoms | Depressive symptoms | Sleep | Hot flashes | Quality of life | DEPRESSION SCALE | BREAST-CANCER SURVIVORS | Actigraphy | MASS-SPECTROMETRY | MENOPAUSAL TRANSITION | OBSTETRICS & GYNECOLOGY | CORE BODY-TEMPERATURE | PERIMENOPAUSAL WOMEN | MIDDLE-AGED WOMEN | QUALITY-OF-LIFE | POSTMENOPAUSAL WOMEN | Estradiol - metabolism | Sleep Initiation and Maintenance Disorders - etiology | Women's Health | Follow-Up Studies | Hot Flashes - complications | Humans | Middle Aged | Gonadotropin-Releasing Hormone - administration & dosage | Circadian Rhythm | Healthy Volunteers | Sleep - drug effects | Adult | Female | Galvanic Skin Response - physiology | Gonadotropin-Releasing Hormone - agonists | Hot Flashes - chemically induced | sleep | actigraphy | quality-of-life | vasomotor symptoms | depressive symptoms | hot flashes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
by Villiers, de, T.J and Chines, A.A and Palacios, S and Lips, P.T.A.M and Sawicki, A.Z and Levine, A.B and Coeanu, C and Kelepouris, N and Brown, J.P
Osteoporosis International, ISSN 0937-941X, 2011, Volume 22, Issue 2, pp. 567 - 576
Findings from this 5-year phase 3 study of postmenopausal women with osteoporosis showed that bazedoxifene was associated with an overall favorable safety and... 
Postmenopausal | Osteoporosis | Medicine & Public Health | SERMs | Gynecology | Orthopedics | Bazedoxifene | Rheumatology | Tolerability | Safety | Endocrinology | LEVORMELOXIFENE | CLINICAL-TRIAL | ENDOMETRIUM | RALOXIFENE | PREVENTION | ESTROGEN-RECEPTOR MODULATOR | BREAST-CANCER | VERTEBRAL FRACTURE RISK | ENDOCRINOLOGY & METABOLISM | OUTCOMES | ADVERSE EVENTS | Venous Thrombosis - chemically induced | Double-Blind Method | Humans | Middle Aged | Selective Estrogen Receptor Modulators - adverse effects | Treatment Outcome | Osteoporosis, Postmenopausal - drug therapy | Muscle Cramp - chemically induced | Indoles - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Aged, 80 and over | Female | Indoles - therapeutic use | Aged | Hot Flashes - chemically induced | Estrogen | Postmenopausal women | Antagonists | Dosage and administration | Diagnosis | Drug therapy | Women | Clinical trials | Patient safety | Menopause
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights